|
| | TEMAFLOXACIN Basic information |
| Product Name: | TEMAFLOXACIN | | Synonyms: | Teflox;6-Fluoro-1-(2,4-difluorophenyl)-7-(3-methylpiperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid;TeMafloxacin HCl;TEMAFLOXACIN;AKOS 92085;1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl) -4-oxo-3-quinoline-carboxylic acid;1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-quino line-3-carboxylic acid hydrochloride;A-62254 | | CAS: | 108319-06-8 | | MF: | C21H18F3N3O3 | | MW: | 417.38 | | EINECS: | | | Product Categories: | | | Mol File: | 108319-06-8.mol |  |
| | TEMAFLOXACIN Chemical Properties |
| Melting point | >200°C (dec.) | | Boiling point | 608.9±55.0 °C(Predicted) | | density | 1.3372 (estimate) | | storage temp. | 2-8°C(protect from light) | | solubility | Aqueous Acid (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 6.02±0.41(Predicted) | | color | White to Off-White | | Stability: | Hygroscopic |
| | TEMAFLOXACIN Usage And Synthesis |
| Description | Temafloxacin is a fluoroquinolone antibiotic that acts as a DNA topoisomerase inhibitor. It has broad antimicrobial activity against gram-positive and gram-negative bacteria, such as S. pneumoniae, M. hominis, and anaerobic bacteria, including B. fragilis. | | Uses | Antibacterial (microbial DNA topoisomerase
inhibitor). | | Uses | Temafloxacin is an antimicrobial quinolone drug. | | Definition | ChEBI: 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is a quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively. It is a quinolone, an amino acid, a monocarboxylic acid, an organofluorine compound, a secondary amino compound, a tertiary amino compound, a N-arylpiperazine and a quinolone antibiotic. | | Brand name | Omniflox (Abbott);8Omniflox 8Teflox 8Temac. | | World Health Organization (WHO) | Temafloxacin, a quinolone antimicrobial, was introduced in 1991.
Shortly afterwards, its use became associated with severe adverse effects,
including hypoglycaemia, haemolytic anaemia, renal failure, hepatitis and
anaphylactic reactions. This led to its worldwide withdrawal by the manufacturer. |
| | TEMAFLOXACIN Preparation Products And Raw materials |
|
